NDA 017963 · Validus Pharms
Lopressor
Metoprolol Tartrate · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Dec 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1978
Aug 7, 1978
Approved uses
4
Original approval plus efficacy supplements
Registered trials
302
56 Phase 3, 19 recruiting
FAERS reports
86,471
59,888 serious, 9,924 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 14, 2023.
1 IND ICATIONS AND USAGE LOPRESSOR is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension LOPRESSOR is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other...
Mechanism: Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. The relative beta 1...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 27, 1986 Supplement 34 · Efficacy
- Mar 30, 1984 Supplement 24 · Efficacy
- Apr 12, 1983 Supplement 28 · Efficacy
- Aug 7, 1978 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- LOPRESSOR · METOPROLOL TARTRATE 50MG · TABLET, ORAL · Prescription · TE AB
- LOPRESSOR · METOPROLOL TARTRATE 100MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Metoprolol" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial InfarctionPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00222573 · 46,000 participants · Start Jul 1999
Drug: clopidogrel and metoprolol · For: Acute Myocardial Infarction
Sites: Beijing, China; Oxford, United Kingdom
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"Pivotal-lookingCompleted
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIAcademic, hospital or other
NCT03596385 · 8,505 participants · Start Oct 31, 2018 · Primary completion Jan 31, 2025
Drug: Beta blocker · For: Myocardial Infarction
Sites: San Severo, Italy; Alessandria, Italy; Ancona, Italy · 111 sites in all
- POISE Trial: Perioperative Ischemic Evaluation StudyPivotal-lookingTerminated
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT00182039 · 8,351 participants · Start Oct 2002 · Primary completion Jul 2007
Drug: Metoprolol controlled release (CR); Placebo · For: Cardiovascular Diseases
Sites: Hamilton, Canada
- Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)Pivotal-lookingStatus unknown
Karolinska InstitutetAcademic, hospital or other
NCT03278509 · 5,000 participants (planned) · Start Sep 11, 2017 · Primary completion Nov 16, 2023
Drug: Metoprolol Succinate; Bisoprolol · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction; ST Elevation Myocardial Infarction
Sites: Danderyd, Sweden
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic FunctionPivotal-lookingActive, not recruiting
Oslo University HospitalAcademic, hospital or other
NCT03646357 · 2,895 participants · Start Oct 1, 2018 · Primary completion Apr 4, 2025
Drug: Betablocker · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction; ST Elevation Myocardial Infarction
Sites: Arendal, Norway; Bergen, Norway; Bodø, Norway · 20 sites in all
- Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection FractionPivotal-lookingActive, not recruiting
Bispebjerg HospitalAcademic, hospital or other
NCT03778554 · 2,760 participants (planned) · Start Dec 17, 2018 · Primary completion Apr 1, 2025
Drug: Metoprolol Succinate; Bisoprolol and 2 more · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction (nSTEMI); ST Elevation Myocardial Infarction
Sites: Copenhagen, Denmark
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue5,878
- nausea5,108
- dyspnoea5,035
- diarrhoea5,014
- dizziness3,953
- death3,874
- drug ineffective3,796
- pain3,713
- asthenia3,684
- headache3,255
- fall3,119
- myocardial infarction3,041
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,399 |
| 2005 | 1,811 |
| 2006 | 2,035 |
| 2007 | 1,422 |
| 2008 | 3,265 |
| 2009 | 2,706 |
| 2010 | 3,627 |
| 2011 | 5,835 |
| 2012 | 5,503 |
| 2013 | 2,009 |
| 2014 | 3,994 |
| 2015 | 4,233 |
| 2016 | 5,398 |
| 2017 | 5,594 |
| 2018 | 5,556 |
| 2019 | 5,428 |
| 2020 | 4,735 |
| 2021 | 3,713 |
| 2022 | 3,691 |
| 2023 | 3,488 |
| 2024 | 3,430 |
| 2025 | 4,141 |
| 2026 | 3,456 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lopressor (Metoprolol Tartrate)
2024 spending
$310K
Beneficiaries
257
901 claims
Per beneficiary
$1,204
$2.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $518,195 |
| 2021 | $487,155 |
| 2022 | $459,116 |
| 2023 | $369,969 |
| 2024 | $309,517 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.
Dybro AM, Rasmussen TB, Nielsen RR, et al. · J Am Coll Cardiol 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Poole-Wilson PA, Swedberg K, Cleland JG, et al. · Lancet 2003 · Clinical Trial, Comparative Study
- Metoprolol for the Prevention of Acute Exacerbations of COPD.
Dransfield MT, Voelker H, Bhatt SP, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Metoprolol (Lopressor).
· Med Lett Drugs Ther 1978 · Clinical Trial, Comparative Study
- Effect of metoprolol on chest pain in acute myocardial infarction.
Herlitz J, Hjalmarson A, Holmberg S, et al. · Br Heart J 1984 · Clinical Trial, Randomized Controlled Trial
- Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.
Hegde SM, Wang X, Garcia-Pavia P, et al. · J Am Coll Cardiol 2025 · Randomized Controlled Trial, Comparative Study
Sponsor: Validus Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.